SCHEMBL4370495

SCHEMBL4370495

c1ccc(COc2ccc(C3CO3)cc2OCc2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.47
PDE4B Q07343 1/20 0.47
PDE4C Q08493 1/20 0.47
PDE4D Q08499 1/20 0.47
APP P05067 2/20 0.45
TSHR P16473 1/20 0.44
SLC6A4 P31645 3/20 0.44
HTR2C P28335 3/20 0.43
HTR2B P41595 3/20 0.43
PRMT5 O14744 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
C5AR1 P21730 1/20 0.41
POLB P06746 1/20 0.41
UBE2N P61088 1/20 0.41
KMT2A Q03164 1/20 0.41
SLC2A1 P11166 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8768747 0.87 MRGPRX4 (0.51) TSHRSLC6A4HTR2CHTR2BMAPT
SCHEMBL10464043 0.87 S1PR5 (0.48) PDE4APDE4BPDE4CPDE4DTSHR
SCHEMBL13898921 0.87 FFAR4 (0.49) PDE4APDE4BPDE4CPDE4DAPP
SCHEMBL20041825 0.87 TDP1 (0.45) PDE4APDE4BPDE4CPDE4DAPP
SCHEMBL7146977 0.84 ELANE (0.47) APPTSHRHTR2CHTR2B
SCHEMBL9574268 0.83 FOLH1 (0.58) APPPRMT5L3MBTL1POLBKMT2A
SCHEMBL14095898 0.83 PDE4A (0.40) PDE4APDE4BPDE4CPDE4DAPP
SCHEMBL15680635 0.82 ALDH1A1 (0.49) PDE4APDE4BPDE4CPDE4DAPP
SCHEMBL3987261 0.81 PARP1 (0.48) APPPRMT5L3MBTL1POLBKMT2A
SCHEMBL865598 0.81 POLB (0.54) MAPTTDP1L3MBTL1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601667-B2 Ruthenium/iridium complexes; hydrogenation catalysts KANTO KAGAKU KABUSHIKI KAISHA (JP) 2009-10-13 US disclosed
US-20080234525-A1 Ruthenium/iridium complexes; hydrogenation catalysts NAGOYA INDUSTRIAL SCIENCE RESEARCH INSTITUTE (JP) 2008-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234525-A1 Ruthenium/iridium complexes; hydrogenation catalysts ADH5, ADH1A, ADH1C PDE4A 4793/4885PDE4B 4640/4885PDE4C 4751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.